Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hemangiopericytoma, Malignant 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

vatalanib 1romidepsin 1indolepropanol phosphate 1Watchful Waiting 1Sunitinib 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Polymerase Chain Reaction 1Observation 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Ifosfamide 1Gene Expression Profiling 1Doxorubicin 1Blotting, Western 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hemangiopericytoma, Malignant × vatalanib × Clear all
NCT00348790 2018-10-26

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Northwestern University

Phase 2 Completed
25 enrolled 10 charts
CNSSarcoma

Hemangiopericytoma, Malignant, Brain Neoplasms, Meningioma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡